ATC Group: N06AX12 Bupropion

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AX12 in the ATC hierarchy

Level	Code	Title
`1`	N	Nervous system
`2`	N06	Psychoanaleptics
`3`	N06A	Antidepressants
`4`	N06AX	Other antidepressants
`5`	N06AX12	Bupropion

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	0.3 g

Active ingredients in N06AX12

Active Ingredient
Bupropion
Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit either monoamine oxidase. The mechanism by which bupropion enhances the ability of patients to abstain from smoking is unknown. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.

Related product monographs

Document	Type	Information Source
WELLBUTRIN SR Sustained‑release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
WELLBUTRIN XL Extended-release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ZYBAN Prolonged release tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)